Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Oncology/Hematology Market Research

Global Lung Cancer Genomic Testing Market By Component (Products v/s Services), By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others), By Panel Type (Single Pa

Best Price Guarantee Length Publisher Published Date SKU
from $4,900 115 Pages TechSci Research October, 2022 TCSI17417724
Best Price Guarantee
Price from $4,900
Length 115 Pages
Publisher TechSci Research
Published Date October, 2022
SKU TCSI17417724

Global Lung Cancer Genomic Testing Market By Component (Products v/s Services), By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others), By Panel Type (Single Panel v/s Multi-Gene Panel), By Sample Type (Tissue Biopsy v/s Liquid Biopsy), By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others), and By Region, Competition Forecast and Opportunities, 2027

The global lung cancer genomic testing market is still at an early stage and is anticipated to witness a steady CAGR in the forecast period, 2023-2027. Factors such as growing awareness and adoption of lung cancer genomic testing and the high prevalence of lung cancer worldwide are the primary drivers for the global lung cancer genomic testing market. The other factors include the high-end investments by the private and public players to facilitate research and development activities to cure lung cancer and the favorable government policies and campaigns to create awareness about different cancer types. Also, the rapid shift of the healthcare system towards precision medicine and diagnostics technology is expected to boost the adoption of lung cancer genomic testing by healthcare facilities to help them make informed decisions.

Increased Awareness about Lung Cancer Genomic Testing Drives the Market Growth

The growing popularity of personalized medicine in the healthcare industry is expected to transform the way diseases such as lung cancer are being treated in healthcare facilities. Personalized medicine involves the study of cells obtained from biopsy and observing if there are any genetic mutations that can be linked with the cancer suffering patient. As certain chemotherapy drugs are either more or less effective than the others with specific mutations, genomic testing or molecular analysis can be used to determine which therapies can benefit an individual suffering from cancer. Genetic information obtained through genomic testing is useful to predict the chances of cancer returning to the human body and make other important decisions about surgery or radiation therapy. Samples obtained from people with lung cancer are checked by studying the genetic mutations known to be vital in the development of the disease. Treatment can be personalized, which can prove to be useful for patients and increase the effectiveness of treatment. Therefore, increased awareness about personalized medicine and the benefits obtained from genomic testing is expected to accelerate the global lung cancer genomic testing market growth over the forecast period.

High Prevalence of Lung Cancer Boosts the Market Growth

The rising prevalence of lung cancer, and the large number of patients undergoing screening and treatment are increasing the demand for lung cancer genomic testing services worldwide. Lung cancer, including both small cell and non-small cell, is one of the most common kinds of cancer. According to The American Cancer Society, the estimates for lung cancer in the United States in 2022 are about 236,740 new cases of lung cancer and about 130,180 deaths from lung cancer. It generally occur in the old age population and in the people who smoke on a daily basis. Also, according to World Health Organization, cancer is the leading cause of death and accounted for nearly 10 million deaths in 2020, with which lung cancer death cases were 1.80 million across the globe. Therefore, there is a massive demand for technologies that can lower cancer incidence and mortality rate, and the reliability and benefits of genomic testing are expected to propel global lung cancer genomic testing market growth over the next five years.

Market Segmentation

The global lung cancer genomic testing market is segmented into component, technology, panel type, sample type, end user, regional distribution, and competitive landscape. Based on component, the market is divided into products v/s services. Based on technology, the market is divided into next generation sequencing, polymerase chain reactions, fluorescence in situ hybridization (FISH)/in situ hybridization (ISH), and others. Based on panel type, the market is divided into single panel v/s multi-gene panel. Based on sample type, the market is divided into tissue biopsy v/s liquid biopsy. Based on end user, the market is divided into academic & research institutions, hospitals & clinics, diagnostic laboratories, others. The market analysis also studies the regional segmentation, divided among North American region, Asia-Pacific region, European region, South American region, and Middle East & African region. In terms of country, the United States is expected to be a lucrative market due to the early adoption of advanced technologies by the healthcare sector and the high prevalence of lung cancer in the country.

Market Players

Qiagen NV, Agilent Technologies, Inc., Thermo Fischer Scientific, Inc., Quest Diagnostics, Inc., Laboratory Corporation of America Holdings, Centogene N.V., CeGaT GmbH, Illumina, Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Inc., CD Genomics, NeoGenomics Laboratories, OPKO Health, Inc., OncoDNA, Admera Health are the major market players operating in the global lung cancer genomic testing market.

Report Scope:

In this report, global lung cancer genomic testing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Lung Cancer Genomic Testing Market, By Component:
  • Products
  • Services
  • Lung Cancer Genomic Testing Market, By Technology:
  • Next Generation Sequencing
  • Polymerase Chain Reactions
  • Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)
  • Others
  • Lung Cancer Genomic Testing Market, By Panel Type:
  • Single Panel
  • Multi-Gene Panel
  • Lung Cancer Genomic Testing Market, By Sample Type:
  • Tissue Biopsy
  • Liquid Biopsy
  • Lung Cancer Genomic Testing Market, By End User:
  • Academic & Research Institutions
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others
  • Lung Cancer Genomic Testing Market, By Region:
  • North America
  • United States
  • Mexico
  • Canada
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Denmark
  • Netherlands
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Turkey
Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global lung cancer genomic testing market.

Company Information
  • Detailed analysis and profiling of additional market players (up to five).
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order. Single User license will be delivered in PDF format without printing rights


1. Service Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Lung Cancer Genomic Testing Market
5. Voice of Customer
5.1. Lung Cancer Prevalence, By Type
5.2. Lung Cancer Prevalence, By Gender
5.3. Lung Cancer Prevalence, By Age Group
5.4. Lung Cancer Prevalence, By Region
5.5. Causes of Lung Cancer
6. Clinical Trial Analysis
7. Patent Analysis
8. Global Lung Cancer Genomic Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Component (Products v/s Services)
8.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others)
8.2.3. By Panel Type (Single Panel v/s Multi-Gene Panel)
8.2.4. By Sample Type (Tissue Biopsy v/s Liquid Biopsy)
8.2.5. By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others)
8.2.6. By Company (2021)
8.2.7. By Region
8.3. Product Market Map
9. North America Lung Cancer Genomic Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Component
9.2.2. By Technology
9.2.3. By Panel Type
9.2.4. By Sample Type
9.2.5. By End User
9.2.6. By Country
9.3. Policy & Regulatory Landscape
9.4. North America: Country Analysis
9.4.1. United States Lung Cancer Genomic Testing Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Component
9.4.1.2.2. By Technology
9.4.1.2.3. By Panel Type
9.4.1.2.4. By Sample Type
9.4.1.2.5. By End User
9.4.2. Mexico Lung Cancer Genomic Testing Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Component
9.4.2.2.2. By Technology
9.4.2.2.3. By Panel Type
9.4.2.2.4. By Sample Type
9.4.2.2.5. By End User
9.4.3. Canada Lung Cancer Genomic Testing Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Component
9.4.3.2.2. By Technology
9.4.3.2.3. By Panel Type
9.4.3.2.4. By Sample Type
9.4.3.2.5. By End User
10. Europe Lung Cancer Genomic Testing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Component
10.2.2. By Technology
10.2.3. By Panel Type
10.2.4. By Sample Type
10.2.5. By End User
10.2.6. By Country
10.3. Policy & Regulatory Landscape
10.4. Europe: Country Analysis
10.4.1. France Lung Cancer Genomic Testing Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Component
10.4.1.2.2. By Technology
10.4.1.2.3. By Panel Type
10.4.1.2.4. By Sample Type
10.4.1.2.5. By End User
10.4.2. Germany Lung Cancer Genomic Testing Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Component
10.4.2.2.2. By Technology
10.4.2.2.3. By Panel Type
10.4.2.2.4. By Sample Type
10.4.2.2.5. By End User
10.4.3. United Kingdom Lung Cancer Genomic Testing Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Component
10.4.3.2.2. By Technology
10.4.3.2.3. By Panel Type
10.4.3.2.4. By Sample Type
10.4.3.2.5. By End User
10.4.4. Italy Lung Cancer Genomic Testing Market Outlook
10.4.4.1. Market Size & Forecast
10.4.4.1.1. By Value
10.4.4.2. Market Share & Forecast
10.4.4.2.1. By Component
10.4.4.2.2. By Technology
10.4.4.2.3. By Panel Type
10.4.4.2.4. By Sample Type
10.4.4.2.5. By End User
10.4.5. Spain Lung Cancer Genomic Testing Market Outlook
10.4.5.1. Market Size & Forecast
10.4.5.1.1. By Value
10.4.5.2. Market Share & Forecast
10.4.5.2.1. By Component
10.4.5.2.2. By Technology
10.4.5.2.3. By Panel Type
10.4.5.2.4. By Sample Type
10.4.5.2.5. By End User
10.4.6. Denmark Lung Cancer Genomic Testing Market Outlook
10.4.6.1. Market Size & Forecast
10.4.6.1.1. By Value
10.4.6.2. Market Share & Forecast
10.4.6.2.1. By Component
10.4.6.2.2. By Technology
10.4.6.2.3. By Panel Type
10.4.6.2.4. By Sample Type
10.4.6.2.5. By End User
10.4.7. Netherlands Lung Cancer Genomic Testing Market Outlook
10.4.7.1. Market Size & Forecast
10.4.7.1.1. By Value
10.4.7.2. Market Share & Forecast
10.4.7.2.1. By Component
10.4.7.2.2. By Technology
10.4.7.2.3. By Panel Type
10.4.7.2.4. By Sample Type
10.4.7.2.5. By End User
11. Asia-Pacific Lung Cancer Genomic Testing Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Component
11.2.2. By Technology
11.2.3. By Panel Type
11.2.4. By Sample Type
11.2.5. By End User
11.2.6. By Country
11.3. Policy & Regulatory Landscape
11.4. Asia-Pacific: Country Analysis
11.4.1. China Lung Cancer Genomic Testing Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1. By Value
11.4.1.2. Market Share & Forecast
11.4.1.2.1. By Component
11.4.1.2.2. By Technology
11.4.1.2.3. By Panel Type
11.4.1.2.4. By Sample Type
11.4.1.2.5. By End User
11.4.2. India Lung Cancer Genomic Testing Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1. By Value
11.4.2.2. Market Share & Forecast
11.4.2.2.1. By Component
11.4.2.2.2. By Technology
11.4.2.2.3. By Panel Type
11.4.2.2.4. By Sample Type
11.4.2.2.5. By End User
11.4.3. South Korea Lung Cancer Genomic Testing Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1. By Value
11.4.3.2. Market Share & Forecast
11.4.3.2.1. By Component
11.4.3.2.2. By Technology
11.4.3.2.3. By Panel Type
11.4.3.2.4. By Sample Type
11.4.3.2.5. By End User
11.4.4. Japan Lung Cancer Genomic Testing Market Outlook
11.4.4.1. Market Size & Forecast
11.4.4.1.1. By Value
11.4.4.2. Market Share & Forecast
11.4.4.2.1. By Component
11.4.4.2.2. By Technology
11.4.4.2.3. By Panel Type
11.4.4.2.4. By Sample Type
11.4.4.2.5. By End User
11.4.5. Australia Lung Cancer Genomic Testing Market Outlook
11.4.5.1. Market Size & Forecast
11.4.5.1.1. By Value
11.4.5.2. Market Share & Forecast
11.4.5.2.1. By Component
11.4.5.2.2. By Technology
11.4.5.2.3. By Panel Type
11.4.5.2.4. By Sample Type
11.4.5.2.5. By End User
12. South America Lung Cancer Genomic Testing Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Component
12.2.2. By Technology
12.2.3. By Panel Type
12.2.4. By Sample Type
12.2.5. By End User
12.2.6. By Country
12.3. Policy & Regulatory Landscape
12.4. South America: Country Analysis
12.4.1. Brazil Lung Cancer Genomic Testing Market Outlook
12.4.1.1. Market Size & Forecast
12.4.1.1.1. By Value
12.4.1.2. Market Share & Forecast
12.4.1.2.1. By Component
12.4.1.2.2. By Technology
12.4.1.2.3. By Panel Type
12.4.1.2.4. By Sample Type
12.4.1.2.5. By End User
12.4.2. Argentina Lung Cancer Genomic Testing Market Outlook
12.4.2.1. Market Size & Forecast
12.4.2.1.1. By Value
12.4.2.2. Market Share & Forecast
12.4.2.2.1. By Component
12.4.2.2.2. By Technology
12.4.2.2.3. By Panel Type
12.4.2.2.4. By Sample Type
12.4.2.2.5. By End User
12.4.3. Colombia Lung Cancer Genomic Testing Market Outlook
12.4.3.1. Market Size & Forecast
12.4.3.1.1. By Value
12.4.3.2. Market Share & Forecast
12.4.3.2.1. By Component
12.4.3.2.2. By Technology
12.4.3.2.3. By Panel Type
12.4.3.2.4. By Sample Type
12.4.3.2.5. By End User
13. Middle East and Africa Lung Cancer Genomic Testing Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Component
13.2.2. By Technology
13.2.3. By Panel Type
13.2.4. By Sample Type
13.2.5. By End User
13.2.6. By Country
13.3. Policy & Regulatory Landscape
13.4. MEA: Country Analysis
13.4.1. Turkey Lung Cancer Genomic Testing Market Outlook
13.4.1.1. Market Size & Forecast
13.4.1.1.1. By Value
13.4.1.2. Market Share & Forecast
13.4.1.2.1. By Component
13.4.1.2.2. By Technology
13.4.1.2.3. By Panel Type
13.4.1.2.4. By Sample Type
13.4.1.2.5. By End User
13.4.2. South Africa Lung Cancer Genomic Testing Market Outlook
13.4.2.1. Market Size & Forecast
13.4.2.1.1. By Value
13.4.2.2. Market Share & Forecast
13.4.2.2.1. By Component
13.4.2.2.2. By Technology
13.4.2.2.3. By Panel Type
13.4.2.2.4. By Sample Type
13.4.2.2.5. By End User
13.4.3. Saudi Arabia Lung Cancer Genomic Testing Market Outlook
13.4.3.1. Market Size & Forecast
13.4.3.1.1. By Value
13.4.3.2. Market Share & Forecast
13.4.3.2.1. By Component
13.4.3.2.2. By Technology
13.4.3.2.3. By Panel Type
13.4.3.2.4. By Sample Type
13.4.3.2.5. By End User
13.4.4. UAE Lung Cancer Genomic Testing Market Outlook
13.4.4.1. Market Size & Forecast
13.4.4.1.1. By Value
13.4.4.2. Market Share & Forecast
13.4.4.2.1. By Component
13.4.4.2.2. By Technology
13.4.4.2.3. By Panel Type
13.4.4.2.4. By Sample Type
13.4.4.2.5. By End User
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
16. SWOT Analysis: Global Lung Cancer Genomic Testing Market
17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)
17.1. Qiagen NV
17.2. Agilent Technologies, Inc.
17.3. Thermo Fischer Scientific, Inc.
17.4. Quest Diagnostics, Inc.
17.5. Laboratory Corporation of America Holdings
17.6. Centogene N.V.
17.7. CeGaT GmbH
17.8. Illumina, Inc.
17.9. F. Hoffmann-La Roche AG
17.10. Abbott Laboratories, Inc.
17.11. CD Genomics
17.12. NeoGenomics Laboratories
17.13. OPKO Health, Inc.
17.14. OncoDNA
17.15. Admera Health
18. Strategic Recommendations

$4,900
$5,900
$8,900

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings